Association of MPOD Values With Blue Light.

NCT04779398 | Completed

• 1 other identifier: 2019002736
• Study Type: observational
• Target: 96
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to investigate in healthy adults 18-65 years of age the association of electronic device blue light exposure and macular pigment optical density (MPOD) considering usual dietary intake of lutein and zeaxanthin (L/Z) as confirmed by serum lutein and zeaxanthin concentrations. It is hypothesised in healthy adults 18-65 years of age:

1. 1.Higher usual daily electronic device blue light exposure will be negatively correlated with MPOD value.
2. 2.Usual dietary intake of L/Z will be positively correlated with MPOD value.
3. 3.L/Z concentration will be positively correlated with MPOD value.
4. 4.Usual dietary intake of L/Z will be positively correlated with plasma L/Z concentrations.
5. 5.Higher usual intake of L/Z will mitigate the effect of higher electronic device exposure on MPOD value.

Conditions

Age Related Macular Degeneration

Keywords

macular pigment optical density; lutein; zeaxanthin; dietary intake; blue light

Outcome Measures

Primary Outcomes (1)

• Macular Pigment Optical Density

  Machine: Macular Pigment Screener II (Elektron Eye Technology). The non-invasive test uses heterochromatic flicker photometry.

  Triplicate measurement day 1

Secondary Outcomes (3)

• Dietary intake of lutein and zeaxanthin

  Retrospective intake prior one month

• Usual use of electronic devices.

  Retrospective use of devices prior 3 months.

• Blood lutein and zeaxanthin concentration

  Single sample drawn on day of study visit (Day 1).

Other Outcomes (1)

• Dietary intake of lutein and zeaxanthin on day prior to study visit.

  Intake over single day prior to study visit (Day 1).

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Healthy males and females, 18-65 years of age from Brisbane and surroudning areas, Australia.

You may qualify if:

• Male and females 18 to 65 years.
• Generally healthy.
• No participant reported history of clinically significant medical conditions including, but not limited to, cardiovascular, neurological, psychiatric, renal, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled.
• Non-smoker

You may not qualify if:

• Participant reported diagnosis of serious ocular conditions (e.g. cataracts, glaucoma, diabetic retinopathy, retinitis pigmentosa, Stagardt's disease)
• Participant reported diagnosis, or current treatment of age-related macular degeneration.
• Participant reported diagnosis of epilepsy.
• Current or past smoker (within last 12 months).
• Under 18 or over 65 years of age.

Sponsors & Collaborators

• The University of Queensland: lead

Study Sites (1)

School of Human Movement and Nutrition Sciences, The University of Queensland

Saint Lucia, Queensland, 4067, Australia

Location

Related Publications (7)

• Chiu CJ, Chang ML, Zhang FF, Li T, Gensler G, Schleicher M, Taylor A. The relationship of major American dietary patterns to age-related macular degeneration. Am J Ophthalmol. 2014 Jul;158(1):118-127.e1. doi: 10.1016/j.ajo.2014.04.016. Epub 2014 Apr 29.

  PMID: 24792100 BACKGROUND

• Wu J, Seregard S, Algvere PV. Photochemical damage of the retina. Surv Ophthalmol. 2006 Sep-Oct;51(5):461-81. doi: 10.1016/j.survophthal.2006.06.009.

  PMID: 16950247 BACKGROUND

• Algvere PV, Marshall J, Seregard S. Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand. 2006 Feb;84(1):4-15. doi: 10.1111/j.1600-0420.2005.00627.x.

  PMID: 16445433 BACKGROUND

• Widomska J, Subczynski WK. Why has Nature Chosen Lutein and Zeaxanthin to Protect the Retina? J Clin Exp Ophthalmol. 2014 Feb 21;5(1):326. doi: 10.4172/2155-9570.1000326.

  PMID: 24883226 BACKGROUND

• Stringham JM, Stringham NT, O'Brien KJ. Macular Carotenoid Supplementation Improves Visual Performance, Sleep Quality, and Adverse Physical Symptoms in Those with High Screen Time Exposure. Foods. 2017 Jun 29;6(7):47. doi: 10.3390/foods6070047.

  PMID: 28661438 BACKGROUND

• Williams R, Bakshi S, Ostrin EJ, Ostrin LA. Continuous Objective Assessment of Near Work. Sci Rep. 2019 May 6;9(1):6901. doi: 10.1038/s41598-019-43408-y.

  PMID: 31061427 BACKGROUND

• van der Veen RL, Berendschot TT, Hendrikse F, Carden D, Makridaki M, Murray IJ. A new desktop instrument for measuring macular pigment optical density based on a novel technique for setting flicker thresholds. Ophthalmic Physiol Opt. 2009 Mar;29(2):127-37. doi: 10.1111/j.1475-1313.2008.00618.x.

  PMID: 19236582 BACKGROUND

Related Links

• Recruitment page with introductory information about study.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Plasma blood sample.

MeSH Terms

Conditions

Macular Degeneration

Condition Hierarchy (Ancestors)

Retinal Degeneration; Retinal Diseases; Eye Diseases

Study Officials

• Veronique Chachay, PhD

  The University of Queensland

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 24, 2021
• First Posted: March 3, 2021
• Study Start: September 25, 2020
• Primary Completion: March 31, 2022
• Study Completion: March 31, 2022
• Last Updated: May 19, 2022

Record last verified: 2022-05

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)